Neurological Surgery 脳神経外科51巻5号

2023年09月発行

特集 臨床脳神経外科医にとってのWHO脳腫瘍分類第5版 Ⅱ 成人悪性脳腫瘍

膠芽腫，IDH野生型

著者： 柴原一陽¹ 隈部俊宏¹

所属機関： ¹北里大学医学部脳神経外科

ページ範囲：P.821 - P.828

Point
・WHO脳腫瘍分類第5版で膠芽腫の定義が変更となった．
・MRI画像から膠芽腫と確定診断することは必ずしも容易ではない．
・膠芽腫治療におけるがん遺伝子パネル検査および分子標的薬の役割は期待できる．

参考文献

1）Stupp R, et al；European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups, National Cancer Institute of Canada Clinical Trials Group：Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352：987-996, 2005

2）Gilbert MR, et al：A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med 370：699-708, 2014

3）Chinot OL, et al：Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med 370：709-722, 2014

4）Stupp R, et al：Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma：a randomized clinical trial. JAMA 318：2306-2316, 2017

5）Brat DJ, et al：cIMPACT-NOW update 3：recommended diagnostic criteria for “Diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade Ⅳ”. Acta Neuropathol 136：805-810, 2018

6）Grogan D, et al：Clinical and radiographic characteristics of diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma：a single institution review. J Neurooncol 157：187-195, 2022

7）Tesileanu CMS, et al：Survival of diffuse astrocytic glioma, IDH1/2 wildtype, with molecular features of glioblastoma, WHO grade Ⅳ：a confirmation of the cIMPACT-NOW criteria. Neuro Oncol 22：515-523, 2020

-wildtype diffuse astrocytic glioma with molecular features of glioblastoma. Acta Neuropathol 142：323-338, 2021

9）Lee D, et al：Diffuse astrocytic glioma, IDH-Wildtype, with molecular features of glioblastoma, WHO grade Ⅳ：a single-institution case series and review. J Neurooncol 152：89-98, 2021

10）Keime-Guibert F, et al；Association of French-Speaking Neuro-Oncologists：Radiotherapy for glioblastoma in the elderly. N Engl J Med 356：1527-1535, 2007

11）Perry JR, et al；Trial Investigators：Short-course radiation plus temozolomide in elderly patients with glioblastoma. N Engl J Med 376：1027-1037, 2017

F-fluorodeoxyglucose positron emission tomography. Neuroradiology 55：135-143, 2013

13）Kandalgaonkar P, et al：Predicting IDH subtype of grade 4 astrocytoma and glioblastoma from tumor radiomic patterns extracted from multiparametric magnetic resonance images using a machine learning approach. Front Oncol 12：879376, 2022　doi:10.3389/fonc.2022.879376

14）Lazaridis L, et al：Precision neuro-oncology：a pilot analysis of personalized treatment in recurrent glioma. J Cancer Res Clin Oncol 149：3513-3526, 2023

15）Vivas-Buitrago T, et al：Influence of supramarginal resection on survival outcomes after gross-total resection of IDH-wild-type glioblastoma. J Neurosurg 136：1-8, 2021　doi:10.3171/2020.10.JNS203366

16）Li YM, et al：The influence of maximum safe resection of glioblastoma on survival in 1229 patients：can we do better than gross-total resection? J Neurosurg 124：977-988, 2016

17）Jackson C, et al：A systematic review and meta-analysis of supratotal versus gross total resection for glioblastoma. J Neurooncol 148：419-431, 2020

18）Shibahara I, et al：Role of the parietooccipital fissure and its implications in the pathophysiology of posterior medial temporal gliomas. J Neurosurg 137：505-514, 2022